31 results about "Demethylating agent" patented technology

Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.

The invention describs a method of producing cells for transplantation into myocardial tissue of a mammal. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) passage culturing two times said bone marrow stem cells under conditions that maintain the characteristics of bone marrow stem cells; (c) culturing said bone marrow stem cells in cardiac specific media to differentiate into cardiomyogenic cells; and (d) collecting the cells of step (c) when about 80 to 90% of said cells are cardiomyogenic cells. The cardiomyogenic cells induced according to the method can be clinically applied more suitably than those induced using demethylating agent such as 5-azacytidine, and therefore, they provide induced bone marrow stem cells of a mammal into cardiomyocytes having high rates of cell incorporation and cell survival for treating a mammal (e.g., a human) diagnosed as having a disorder characterized by insufficient cardiac function.

An object of the present invention is to provide a method for transdifferentiating a mature cell without using a DNA methylating agent or a DNA demethylating agent. The present invention provides a method for transdifferentiating a finally differentiated mature cell having a first differentiation phenotype into a finally differentiated mature cell having a second differentiation phenotype that differs from the above first differentiation phenotype by changing culture conditions for the finally differentiated mature cell having the first differentiation phenotype, wherein culture conditions suitable for culturing the finally differentiated mature cell having the above first differentiation phenotype are changed to culture conditions suitable for culturing the finally differentiated mature cell having the above second differentiation phenotype.

Provided herein are pharmaceutical compositions and methods for treating disorders characterized by reduced expression of anti-oxidative stress enzymes in a subject. In one aspect, the present invention provides a method for inducing expression of anti-oxidative stress enzymes in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a demethylating agent. The demethylating agent includes a phytochemical that induces expression of Nrf2 and Nrf2-mediated genes expressing anti-oxidative stress. Such phytochemicals include indoles, such as 3,3′-diindolylmethane (DIM) and indole-3-carbinol (I3C), and isothiocyanates, such as phenethyl isothiocyanate (PEITC) and sulforaphane (SFN).

The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, or a DNA demethylating agent and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

The present invention relates to an improved process for O-demethylating methoxy substituted morphinan-6-one derivatives using AlCl3 as a demethylating agent in a reaction-inert solvent having a water content ranging from 0.1% wt to 0.8% wt. 10.